2026 Cell and Gene Therapy Predictions

The cell and gene therapy industry is entering one of the most revolutionary periods in modern healthcare. With a premier emphasis on rare genetic disorders, the CGT industry has expeditiously emerged into a multi-billion-dollar commercial ecosystem that covers oncology, autoimmune diseases, cardiovascular disorders, neurological conditions, ophthalmology, regenerative medicine, & latest gene editing technologies. Gradually, the industry is shifting from scientific validation to industrial-scale commercialization. In 2026, leading firms are emphasizing rapid scale-up of production, lowering treatment prices, strengthening reimbursement, and expanding clinical applications.

According to Towards Healthcare, the global cell and gene therapy market registered USD 8.94 billion in 2025 and is estimated to expand to US$ 10.44 billion in 2026. During the forecast period, the market is projected to reach USD 47.18 billion by 2035, which shows a rapid expansion at 18.1% CAGR.

Inclusion of several catalysts is empowering the overall industry progression, including

• Elevating commercial adoption of CAR-T therapies
• Surge of gene editing technologies, like CRISPR
• Rising approvals for rare disease therapies
• Growing investment in manufacturing facilities
• Excellent regulatory landscapes throughout the world
• Faster innovation in viral & non-viral delivery systems
• Escalating payer acceptance of one-time curative treatments

Today, oncology is underlined as the dominant therapeutic area globally, while surging innovations are shifting towards CVD, autoimmune disorders, neurological diseases, metabolic disorders, & regenerative medicine. At the end of 2026, CGT industry experts expect the industry to become substantially larger, more competitive, and more global, and to be one of the fastest-growing markets in the healthcare sector in the coming era.

An Eye on the Cell and Gene Therapy Market During 2025-2035

The above statistics demonstrate that by 2035, the CGT industry will grow more than 5x, and overall commercial revenues will be driven by approved therapies rather than research funding.

However, another key area is investment, where investors are consistently prioritizing advanced therapies. In 2026, prominent expected trends are consistent venture capital investment in next-generation platforms, strategic licensing deals, manufacturing alliances, surging M&A activity and rising investment by huge pharma leaders. On the other hand, across the manufacturing landscape, North America presents notable growth, accelerating expansion in Europe, and growing investment across Asia-Pacific.

Why is 2026 Highlighted as a Crucial Year Around the CGT Industry?

Eventual massive advancement efforts are promoting diverse structural trends simultaneously; the industry is broadly pushing robustness throughout research, manufacturing, regulation, reimbursement, and commercialization.  Despite earlier years, companies in 2026 are actively stepping away from treating dozens of patients per year to treating more than hundreds. Whereas the manufacturing firms are seeking innovations, such as automation, closed manufacturing systems, and digital quality control, that enhance scalability while reducing production expenses. Additionally, many healthcare bodies have gained drastically more experience assessing advanced therapies, resulting in more predictable approval roadmaps. Day by day, the cell and gene therapy industry is transitioning toward vast patient populations, coupled with maintaining prominent investments in cell therapy, gene therapy, gene editing, or regenerative medicine.

Specifying Key Predictions of the Cell and Gene Therapy Industry

2026 Prediction #1: Commercial Cell Therapy Will Enter a Novel Progression Phase

In the last few years, previous generations of cell therapies achieved addressable clinical efficacy but also went through significant hurdles regarding production complexity, logistics, reimbursement, and treatment capacity. Moreover, 2026 has been impelling to overcome gradual barriers, via exploring a wide range of trends, like advanced treatment centers, optimized production turnaround times, outstanding patient referral networks, expanded physician familiarity, and raised payer confidence.

Therefore, commercial shares are estimated to accelerate over clinical trial expansion. With a look at robust commercial revenues, the commercial market will be widely transformed by regional growth, label expansions, earlier-line treatment approvals, production improvement, and international reimbursement.

Predicted Commercial Revenue Distribution (2026)

• CAR-T Cell Therapy: 48%
• Gene Therapy: 34%
• Stem Cell Therapy: 12%
• Other Cell Therapies: 6%

These digits indicate that CAR-T captures a dominant share because of multiple commercial products across hematologic malignancies.

Moreover, this showcases that commercial implementation will become just as pivotal as scientific innovation. Many players capable of expanding manufacturing efficiently are estimated to surpass competitors depending solely on new technologies.

2026 Prediction #2: Gene Editing Will Shift Toward Standard Clinical Adoption

At the beginning, the gene editing sector was restricted to experimental research; technologies such as CRISPR, base editing, and prime editing are now dictating higher encouragement to clinical outcomes. In 2026, gene editing is anticipated to move from proof-of-concept studies toward expansive clinical validation. Various areas are attracting substantial attention, such as sickle cell disease, beta-thalassemia, muscular disorders, rare metabolic diseases, and liver diseases. Latest editing technologies also give greater precision, reduced off-target effects, enhanced durability, and excellent safety profiles.

Estimated Technology Share Within Gene Therapy Pipeline

• CRISPR-based Editing: 38%
• Zinc Finger Nucleases: 8%
• TALEN: 6%
• Base Editing: 16%
• Prime Editing: 9%
• Other Technologies: 23%

As per this analysis, CRISPR is highlighted as a dominant area, while base editing & prime editing are projected to witness rapid expansion in the predicted timeframe.

However, gene editing will broadly become a domain platform technology instead of a niche research area. Leading firms emerging scalable editing platforms are predicted to attract key investment.

2026 Prediction #3: Oncology will Continuously Dominate, but Autoimmune Diseases will Become the Next Expansion Frontier

Nowadays, oncology accounts for well over half of the industry’s clinical pipeline. With an emphasis on significant diversification, the industry is experiencing autoimmune diseases, like lupus, multiple sclerosis, rheumatoid arthritis, myasthenia gravis, etc., developing as highly encouraging applications for advanced cell therapies. Early clinical evidence demonstrates that engineered immune cells may induce deep & durable remissions in selected autoimmune conditions, attracting major interest from biopharma players & investors.

Projected Pipeline Share by Therapeutic Area

• Oncology: 62%
• Rare Genetic Diseases: 16%
• Autoimmune Diseases: 8%
• Neurology: 5%
• Cardiovascular: 3%
• Ophthalmology: 3%
• Other Diseases: 3%

According to these shares, oncology holds the largest share, whereas autoimmune diseases are predicted to record the fastest growth in the upcoming years, coupled with maturation of clinical programs.

In addition, innovators are focusing on rising chronic diseases and the commercial potential for cell and gene therapies is estimated to rise significantly, assisting notable double-digit market growth through 2035.

2026 Prediction #4: Manufacturing will Become the Giant Competitive Differentiator

In the last few years, scientific innovation was the prominent determinant of success in cell and gene therapy. In this era, manufacturing excellence will highly separate market companies from developing pioneers. So far, many commercial CGT leaders are facing difficulty proving efficacy, as constant therapies at scale and achieve commercially viable costs. Most eminent breakthroughs include autologous therapies that cover personalized manufacturing for each patient. This majorly needs aggregation of patient cells, transportation to GMP production sites, genetic modification, cell expansion, quality testing, cryopreservation, and delivery back to treatment centers. Alongside, this intricate workflow can take several weeks & contributes crucially to treatment expenses.

To fulfil a growing global demand for advanced therapies, numerous players are currently investing heavily in

• closed-system manufacturing
• digital batch records
• AI-powered quality control
• Automated cell processing
• Robotics
• Real-time manufacturing analytics

These respective modern technologies are anticipated to shrink turnaround times by boosting consistency & reducing batch failure rates.

Estimated Global CGT Manufacturing Infrastructure (2026)

2026 Prediction #5: Non-Viral Gene Delivery Will Gain Lucrative Pace

For many years, viral vectors, like adeno-associated virus (AAV) & lentiviral vectors, have been the spine of gene therapy. Meanwhile, these entities have allowed several commercial successes; they also show limitations, such as restricted cargo capacity, increased production costs, manufacturing risks, and potential immunogenicity & complex scalability. Finally, non-viral delivery technologies are expeditiously reshaping.

To overcome these challenges, 2026 is emerging with novel technologies, like lipid nanoparticles (LNPs), polymer nanoparticles, lipid-polymer hybrid systems, gold nanoparticles, cell-penetrating peptides, & electroporation-based delivery. Specifically, the success of lipid nanoparticle platforms in mRNA vaccines has inspired interest in adjusting these technologies for gene editing & nucleic acid therapeutics.

Estimated Gene Delivery Technology Share (Clinical Pipeline)

• AAV Vectors: 42%
• Lentiviral Vectors: 28%
• Lipid Nanoparticles: 12%
• Non-Viral Platforms: 10%
• Adenoviral Vectors: 5%
• Others: 3%

These statistics indicate that viral vectors remain dominant; non-viral solutions are anticipated to record a rising share of novel pipeline programs in the upcoming years.

Although non-viral delivery approaches provide many strategic advantages, including

• Reduced manufacturing expenses
• Easier scalability
• Frequent dosing potential
• Minimal immune response in some applications
• Expansive therapeutic versatility

In 2026, pioneers involved in successful commercialization of non-viral delivery systems could push addressing certain industry’s most persistent production and access risks. 

2026 Prediction #6: Asia-Pacific will Witness Rapid Growth in the Cell and Gene Therapy Market

North America registers dominance and advances as the global leader in commercialization, research, & investment. On the other hand, Asia-Pacific is expanding as one of the fastest-growing regions for CGT development. Many APAC countries are spurring significant investments in research infrastructure, clinical trial networks, GMP manufacturing, regulatory modernization, talent progression, & biotech funding.

Spotlighting Major Growth Drivers of Different APAC Countries

• China: Eminent and emerging Chinese companies are widely focusing on the quick expansion of CAR-T clinical programs, which spurs the CGT industry. Along with this, China is expanding its domestic manufacturing capacity, coupled with massive government assistance for biotechnology. China is experiencing a huge rise in the geriatric population, highly prone to chronic diseases & further demanding advanced therapies, leading to a surging number of innovative biotech players.
• Japan: The cell and gene therapy market in Japan is registering significant growth, driven by accelerated regenerative medicine pathways and well-established expertise in iPSC technologies. Another driver is early adoption of regenerative therapies across Japan’s healthcare system.
• South Korea: A nation that possesses advanced biologics manufacturing and government-supported innovation programs. Besides this, to bolster novelty in numerous cell and gene therapies, Japanese companies are fostering export abilities.
• Singapore: It has been advancing as a regional hub for translational research through strategic investment in modern therapies. However, Singapore market expansion is mainly propelled by ongoing robust academic-industry collaboration.

Estimated Regional Market Share (2026)

From this analysis, the increasing clinical footprint in APAC shows increasing research capacity & surging involvement in global multi-center studies.

2026 Prediction #7: Ongoing Strategic Alliances, Licensing, and M&A will Support Further Acceleration

In 2026, elevating importance of collaboration pushes large pharmaceutical players to join robust biotech companies to raise accessibility to innovative platforms while lowering development risk. With an emphasis on boosting CGT solutions, numerous well-developed companies are following licensing agreements, platform collaborations, production alliances, joint development initiatives, & strategic acquisitions. These collaborative efforts allow rapid technology adoption & speed up commercialization.

Catalysts Behind Rising Partnerships throughout the CGT Industry

A very specific driver of accelerating partnerships in the cell and gene therapy market is the need for expertise across diverse domains, like cell engineering, gene editing, and viral vector development. Alongside, prospective advances fuel the requirement for manufacturing, regulatory affairs, and commercial operations via continuous alliances among different companies. Some organizations have all of these facilities in-house, which makes partnerships a strategic necessity.

Projected Types of Industry Deals (2026)

• Licensing Agreements: 34%
• Research Collaborations: 26%
• Manufacturing Partnerships: 18%
• Mergers & Acquisitions: 12%
• Commercial Partnerships: 10%

However, the licensing model is expected to be a preferred one, which enables developers to monetize promising technologies while using the commercialization expertise of vast pharma firms.

Unveiling Investment Trends to Impel CGT Industry Expansion

Eventually surging investor interest in the cell and gene therapy stream is propelled by curative treatment potential, broadening notable patient populations, rising regulatory clarity, increasing commercial success stories, and long-term revenue opportunities. Future investment trends will increasingly focus on in vivo gene editing, allogeneic cell therapies, next-generation CAR platforms, non-viral delivery systems, production technologies, coupled with AI for cell engineering, & gene regulation technologies.

Commercial Landscape by Therapy Modality

Day by day, the CGT industry is becoming highly varied, even though some modalities consistently dominate commercial revenues. This mainly encompasses

• CAR-T Cell Therapy: 48%
• Gene Therapy: 34%
• Stem Cell Therapy: 12%
• TCR & NK Cell Therapy: 4%
• Other Cell Therapies: 2%

As here, CAR-T therapies witness lead position because of their established role in hematologic malignancies, whereas gene therapy is advancing into inherited disorders & ophthalmology. However, developing modalities, including NK cell & TCR therapies, are projected to show a rise in share as clinical programs expand.

Roadmap of Investment Priorities for 2026

Especially, biopharmaceutical players are predicted to deploy capital toward technologies with the greater potential for scalability and diversification.

All these priorities indicate the CGT industry’s aim at lowering production complexity, widening therapeutic applications, and enhancing commercial viability.

2026 Prediction #8: Allogeneic Cell Therapies Will Be Explored as a Key Commercial Opportunity

Despite the major efficacy of autologous therapies, specifically in blood cancer, these therapies are facing certain challenges, like tailored manufacturing for each patient, prolonged vein-to -vein timelines, higher production spending, & limited production outcomes with difficult logistics. These limitations have sped up the progression of allogeneic cell therapies, which leverage healthy donor-derived cells to produce validated products. Alongside, these therapies have the potential to lower manufacturing lead times from weeks to days, bolster treatment accessibility, boost production effectiveness, reduce manufacturing expenses through economies of scale & support treatment of vast patient populations. The emergence of gene editing technologies enhances donor cell engineering, while the clinical viability of allogeneic therapies continues to empower.

The global prediction analysis reflects that by 2026, autologous cell therapy is estimated to capture 64% and allogeneic cell therapy to record a 36% share. This shows that autologous will witness dominance, & allogenic will expand the proportion of new clinical programs through 2030.

Focus on therapeutic areas driving allogeneic development

• Hematologic Cancers: Very High
• Solid Tumors: High
• Autoimmune Diseases: High
• Regenerative Medicine: Moderate to High
• Neurological Disorders: Moderate

Across the globe, innovators that successfully recognize restraints, like graft-versus-host disease (GVHD), immune rejection, and persistence, are predicted to reveal substantial commercial opportunities.

2026 Prediction #9: Artificial Intelligence & Digital Technologies will Expedite the Extensive CGT Value Chain

2026 is an era that promotes unification of advanced analytics, machine learning, & digital infrastructure, which further revolutionizes every stage of cell and gene therapy evolution. Regardless of replacing scientific expertise, innovative technologies are boosting decision-making & operational efficiency.

There are several applications of these technologies throughout the CGT ecosystem, such as:

• In the sector of research & discovery, AI and other digital approaches allow identification of new therapeutic targets, improvement in gene-editing designs, estimation of off-target effects, & biomarker discovery.
• However, technologies in clinical studies execute enhanced patient stratification, optimized trial design, predictive enrollment analytics, and digital monitoring of outcomes.
• A scenario of manufacturing capability integrated with AI and digital solutions enables automated quality control, predictive maintenance, batch release optimization, and supply chain transparency.
• In terms of commercialization, automation and AI algorithms support projecting treatment demand, reimbursement analytics, real-world evidence generation, & health economics modeling.

Estimated Adoption of Digital Technologies in CGT Organizations (2026)

• Manufacturing Automation: 72%
• Digital Quality Management: 66%
• Predictive Manufacturing Analytics: 58%
• AI-Powered Drug Discovery: 55%
• Digital Clinical Trial Platforms: 63%
• Supply Chain Analytics: 61%

The widespread adoption of the above technologies will ultimately lower operational expenditures, spur manufacturing uniformity, & reduce development timelines.

The respective digital breakthroughs are extensively assisting in commercialization of thousands of products via digital integration. This unification step supports the management of global manufacturing networks, regulatory documentation, clinical trial data, product traceability, pharmacovigilance, and market access analytics. In addition, robust firms are actively investing early in digital infrastructure to obtain operational and commercial advantages during the forecast period.

2026 Prediction #10: Implementation of Value-Based Reimbursement Will Showcase a Standard Commercial Model

Ability to deliver long-term or even curative benefits via a single administration of cell and gene therapies, leading to a surpass of treatment prices by hundreds or thousands or even millions of dollars per patient. This has further forced payers, providers, and manufacturers to roll out reimbursement models.

To underline these cost concerns, organizations are promoting novel reimbursement approaches, including outcome-based contracts, milestone payments, instalment-based reimbursement, risk-sharing agreements, & performance guarantees. These advanced models will sync payment with clinical outcomes, assisting in understanding budgetary issues while raising patient access.

Furthermore, many factors are fueling adoption, such as

• Growing number of approved CGTs
• Impressive availability of long-term clinical data
• Optimized real-world evidence (RWE) collection
• Rising pressure to present value for money
• Growth into huge patient populations

Alongside, the launch of diverse modern value-based reimbursement will have numerous commercial benefits, including

• Speed up payer acceptance
• Minimize financial risk
• Enhance patient access
• Assist expansive adoption of expensive therapies
• Impel long-term outcome monitoring

In 2030, these models will have higher or broader importance across prominent healthcare systems.

Competitive Landscape: The CGT Industry is Presenting More Diversity

Globally rising demand and advances in cell and gene therapies promote a wide range of stakeholders, from early-stage biotech firms to multinational pharmaceutical companies.

Let’s have a view on the projected competitive landscape in 2026:

• Biotechnology Firms: 58%
• Pharmaceutical Leaders: 22%
• Academic & Research Institutions: 12%
• CDMOs & Production Specialists: 8%

By allowing alliances among these organisations, it expedites innovation & push the shift from the research to commercialisation phase.

Pivotal Role of Eminent Companies to Observe in 2026

2026’s competitive landscape is seeing various leaders that are stepping into advancing therapies, strengthening manufacturing technologies, and developing platforms.

Cell and Gene Therapy Market Outlook Through 2035

Briefing on Strategic Recommendations for Industry Stakeholders

For Biopharmaceutical Companies: The worldwide major biopharma leaders should strengthen their production capabilities to assist industrial-scale production. Also, these firms should focus on investing in allogeneic platforms to bolster scalability & lower expenses, alongside establishing stronger RWE programs to reinforce reimbursement discussions. Additionally, they can differentiate pipelines into autoimmune, cardiovascular, & neurological diseases.

For Investors: In 2026, eminent investors are monitoring entities developing next-generation delivery technologies & manufacturing innovations. Also, they can assess leaders with diversified gene-editing platforms & immersive intellectual property portfolios. During the investment, organizations should consider businesses that support the CGT industry, such as CDMOs, analytics providers, & supply chain specialists.

For Healthcare Providers: Eventual development efforts should elevate readiness for employing advanced therapies through specialized training & building. Providers can ally with producers & payers to assist value-based care models. Recommendations are enabling providers to improve patient identification & referral pathways to enhance access to eligible therapies.

Express Strategic Insights with the Towards Healthcare Cell & Gene Therapy Intelligence Platform

Primarily, the Towards Healthcare Cell & Gene Therapy Intelligence Platform is created to assist worldwide pharma players, biotechnology companies, CDMOs, CROs, investors, consultants, & healthcare strategists. This will help them make informed decisions through interactive dashboards & extensive market monitoring. However, this platform showcases that 1,300+ active pipeline programs are traced throughout multiple therapeutic areas, while 2,500+ clinical trials are monitored globally. Additionally, 5,000+companies have been profiled and standardized, coupled with 500+ global production facilities mapped & evaluated. The platform has been executing inclusion across around 30+ therapeutic areas, with intelligence spanning 50+ nations.

The respective platform is conveying insights via > 20 interactive dashboards, whereas 200+ healthcare reports are published per month. Besides this, it analyzes 2.5 million+ patient-centric data points per year, coupled with 10,000+ hours of expert research support for strategic decisions.

Core Intelligence Modules

The Towards Healthcare intelligence platforms active facilitates actionable insights throughout  

• pipeline intelligence
• clinical trial intelligence
• regulatory & approval tracking
• competitive landscape analysis
• manufacturing & CDMO intelligence
• licensing, M&A, and partnership monitoring
• funding & investment tracking
• technology platform benchmarking
• pricing, reimbursement & market access 
• market forecasting & scenario analysis

While you are investigating acquisition targets, finding licensing opportunities, referencing competitors, or monitoring production growth, the platform offers a combined view of the quickly developing CGT industry.

What are the Latest Funding, Collaborations, & Agreements in the CGT Industry?

• In August 2026, Porton Advanced Solutions Ltd. officially granted a Drug Manufacturing License (Class C) by the NMPA to begin commercial contract manufacturing for Cell and Gene Therapy (CGT) products, spanning its CDMO services from process development and clinical production through to the commercialization stage.
• In August 2026, DNA synthesis specialist DNA Script, along with GE HealthCare, announced awarded up to $26m for a four-year initiative by the Advanced Research Projects Agency for Health (ARPA-H) to spur its Flexible Automation for Scalable Health (FLASH) programme, which creates scalable DNA manufacturing using cell-free bioproduction.
• In August 2026, Genezen & the Raiden Science Foundation (RSF) unlocked a manufacturing partnership for an AAV Serotype 9 gene replacement therapy for UBA5 disorder clinical trials
• In August 2026, the University of Washington received a US$ 1.71 million NIDDK RC2 grant to evolve AI-assisted mini-proteins that epigenetically direct pluripotent stem cells into functional pancreatic islets, underlining a continuous bottleneck in stem cell-based diabetes therapies.
• In July 2026, Immuneel Therapeutics Private Limited & the BRIC Translational Health Science and Technology Institute (THSTI) officially entered into an MoU to develop a collaboration to qualify, evolve, and control a cutting-edge facility for the Current Good Manufacturing Practice (cGMP)-compliant manufacturing of CAR-T cell therapies and Lentiviral Vectors (LVVs). 
• In July 2026, Restore Vision, Inc. & Forge Biologics made a development and manufacturing alliance to foster RV-001, Restore Vision’s investigational GPCR-based optogenetic AAV gene therapy for patients with retinitis pigmentosa.
• In June 2026, Genetix Biotherapeutics tied an exclusive licensing & commercialization agreement with Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO) and its subsidiary SPIMACO Bio, that includes commercialization and localized manufacturing of two FDA-approved gene therapies, i.e. Lyfgenia & Zynteglo, for sickle cell disease & transfusion-dependent beta-thalassemia respectively, across Saudi Arabia & the broader Middle East.
• In June 2026, Made Scientific, Inc. & Pluristyx entered into a strategic partnership to unify Pluristyx Technology, such as GMP iPSC lines and derivative cell types, like induced natural killer (iNK) cells & induced mesenchymal stem cells (iMSCs), into Made Scientific's end-to-end CDMO, providing for global cell and gene therapy pioneers. 
• In May 2026, EnCell signed a contract manufacturing agreement with Ingenium Therapeutics for the NK cell therapy 'IGNK001 (Zengelcell)' to supply clinical trial materials throughout the Japanese market.
• In May 2026, Catalent joined with Elpida Therapeutics to spur late-phase AAV manufacturing for a rare neurological gene therapy, securing exclusive rights across Elpida's broader AAV pipeline.

Expert Insights

According to my analysis, the global cell and gene therapy market reported USD 8.94 billion in 2025 and is anticipated to grow to USD 10.44 billion in 2026, USD 47.18 billion by 2035, with a rapid expansion at 18.1% CAGR in the upcoming years. This overall progression is specifically fueled by a rise in demand for advanced therapies beyond rare diseases into oncology, autoimmune disorders, CVD, neurological diseases, etc. Alongside, the leading companies are prompting the development of CAR-T therapies, with significant breakthroughs in production facilities, research solutions, and clinical developments. For this exploration, global biotech firms, pharma leaders, and healthcare providers are unveiling robust collaborations, licensing agreements, investments & funding. Alongside, reimbursement advances and expedited approvals are also supporting the overall expansion and innovations throughout the CGT ecosystem.